Nora Therapeutics is a Palo Alto, CA-based biotechnology company focused on developing therapeutics to address IVF failure and recurrent pregnancy loss. Its lead compound, NT100, is a novel biologic similar to a naturally occurring protein in the female reproductive tract and may enable embryo implantation and pregnancy maintenance by optimizing maternal-fetal immune tolerance. NT100 is currently being studied in an ongoing Phase 2 trial (THRIVE‑IVF). The company plans to expand development of NT100 by adding a second Phase 2 trial (RESPONSE) in women with unexplained recurrent pregnancy loss. Led by President and CEO Jeffrey K. Tong, Ph.D., Nora intends to use recent financing proceeds to advance these clinical programs. The company closed an $18M Series B to support development of its lead program. Nora Pharmaceuticals develops drugs and devices for women’s reproductive health. The company is based in San Francisco and is operating in stealth (it does not have a website). Nora disclosed that it has some products but did not provide further details. Financially, the company secured $25 million in a first-round financing. The round was led by Burrill & Co., Prospect Venture Partners and Vivo Ventures. The fundraise comes amid heightened investor interest in women’s health, with several peer startups recently raising capital.

Total raised

$43M

Funding rounds

2

Latest round

Series B

Latest activity

Apr 2014